Sustained efficacy of daclizumab beta over up to 6 years continuous treatment and improvements in efficacy outcomes in relapsing RRMS patients who switched from intramuscular interferon beta-1a to subcutaneous daclizumab beta: Interim results from EXTEND

Authors

• Stanley Cohan, Providence Multiple Sclerosis Center, USA.Follow

Document Type

Presentation

Publication Date

2018

Keywords

oregon; providence neuroscience institute

Area of Special Interest

Neurosciences (Brain & Spine)

Specialty/Research Institute

Neurosciences